{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:02:34Z","timestamp":1792389754761,"version":"4.4.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>De-escalation of adjuvant therapy is feasible for select older patients with early-stage breast cancer. It is not known whether we can expand de-escalation options for younger patients by incorporating genomic biomarkers, such as the Oncotype DX 21-gene recurrence score (ODX RS).<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate outcomes of radiotherapy (RT) or endocrine therapy (ET) de-escalation for patients aged 50 to 69 years with early-stage breast cancer and an ODX RS of 18 or below.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study was conducted at a comprehensive cancer center among patients aged 50 to 69 years with T1N0, hormone receptor\u2013positive, ERBB2<\/jats:italic>-negative breast cancer, with an ODX RS of 18 or below. Patients were treated between January 2007 and January 2023 with lumpectomy and ET, with or without adjuvant RT. Patients were considered adherent to ET if they received 5 years of ET or more, or if it was ongoing at last follow-up; nonadherence included halting ET within 5 years after initiation.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Cumulative incidence of locoregional recurrence (LRR) was the primary end point, with death and non\u2013local-regional events as competing risks.<\/jats:p><\/jats:sec>Results<\/jats:title>This analysis included 2249 patients (median [IQR] age, 60 years [55-65 years]) with a median (IQR) follow-up of 63.3 months (34.1-96.0 months), of whom 2075 (92.3%) received RT. The 72-month cumulative incidence of LRR without RT was 8.0% (95% CI, 3.0%-16.0%) vs 1.1% with RT (95% CI, 0.6%-1.7%) (P<\/jats:italic>\u2009&amp;lt;\u2009.001). When stratified by RT and ET adherence, patients receiving RT had the lowest LRR risk regardless of ET duration (72-month LRR: RT and ET adherence, 1.1% [95% CI, 0.6%-2.1%] vs RT and ET nonadherence, 0.9% [95% CI, 0.3%-2.1%]). Adherence to ET alone (without RT) had an estimated 72-month LRR of 5.5% (95% CI, 1.0%-16.0%). Those who did not receive RT and were ET nonadherent had an estimated 72-month LRR of 11.0% (95% CI, 3.3%-25.0%). No association was observed between receipt of RT and OS (P<\/jats:italic>\u2009=\u2009.2).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of patients aged 50 to 69 years who underwent lumpectomy for early-stage breast cancer with ODX RS of 18 or below, we found significantly lower estimated LRR rates among those who completed at least 1 form of adjuvant therapy. For patients willing to accept a low absolute risk, but slightly higher relative risk of LRR with de-escalated therapy, ODX RS may be a valuable tool in selecting younger candidates for RT omission than current guidelines support.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.32305","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:39Z","timestamp":1758121239000},"page":"e2532305","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant Radiation and Endocrine Therapy in Early-Stage Breast Cancer With Low Genomic Risk"],"prefix":"10.1001","volume":"8","author":[{"given":"David Gibbes","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian A.","family":"Boe","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Cuaron","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Isabelle","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beryl","family":"McCormick","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon N.","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif J.","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior Z.","family":"Braunstein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"issue":"9503","key":"zoi250910r1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"issue":"9804","key":"zoi250910r2","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet"},{"issue":"20","key":"zoi250910r3","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1200\/JCO.2002.11.101","article-title":"Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.","volume":"20","author":"Fisher","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi250910r4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/canjclin.52.5.277","article-title":"Standard for breast conservation therapy in the management of invasive breast carcinoma.","volume":"52","author":"Morrow","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"zoi250910r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103670","article-title":"Omission of radiation therapy post breast conserving surgery.","volume":"73","author":"Chua","year":"2024","journal-title":"Breast"},{"key":"zoi250910r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103673","article-title":"De-escalation of loco-regional treatments: time to find a balance.","volume":"73","author":"Gentilini","year":"2024","journal-title":"Breast"},{"issue":"11","key":"zoi250910r7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial.","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi250910r8","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s11864-024-01253-w","article-title":"\u201cWhen less is more\u201d: paradigm shifts in radiation treatment for early-stage breast cancer.","volume":"25","author":"Rhodes","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"zoi250910r9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clon.2022.03.001","article-title":"From 25 fractions to five: how hypofractionation has revolutionised adjuvant breast radiotherapy.","volume":"34","author":"Yarnold","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"7","key":"zoi250910r10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-conserving surgery with or without irradiation in early breast cancer.","volume":"388","author":"Kunkler","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi250910r11","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.","volume":"31","author":"Hughes","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi250910r12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa040587","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.","volume":"351","author":"Hughes","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250910r13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.semradonc.2015.08.002","article-title":"Molecular phenotype, multigene assays, and the locoregional management of breast cancer.","volume":"26","author":"Braunstein","year":"2016","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"zoi250910r14","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/cancers15041260","article-title":"Recent advances in optimizing radiation therapy decisions in early invasive breast cancer.","volume":"15","author":"Riaz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"zoi250910r15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMoa2302344","article-title":"Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer.","volume":"389","author":"Whelan","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi250910r16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.23.02270","article-title":"Omission of radiotherapy after breast-conserving surgery for women with breast cancer with low clinical and genomic risk: 5-year outcomes of IDEA.","volume":"42","author":"Jagsi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5_Supplement","key":"zoi250910r17","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-OT1-12-02","article-title":"Abstract OT1-12-02: Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): a phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer.","volume":"83","author":"Braunstein","year":"2023","journal-title":"Cancer Res"},{"issue":"3","key":"zoi250910r18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10549-017-4358-6","article-title":"Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.","volume":"165","author":"Nitz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"zoi250910r19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi250910r20","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250910r21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10549-017-4381-7","article-title":"21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.","volume":"166","author":"Turashvili","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"zoi250910r22","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","article-title":"Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.","volume":"28","author":"Mamounas","year":"2010","journal-title":"J Clin Oncol"},{"key":"zoi250910r23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40064-015-0840-y","article-title":"The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer.","volume":"4","author":"Thaker","year":"2015","journal-title":"Springerplus"},{"issue":"2","key":"zoi250910r24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10549-012-2072-y","article-title":"Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.","volume":"134","author":"Solin","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"zoi250910r25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2019.5559","article-title":"Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer.","volume":"6","author":"Woodward","year":"2020","journal-title":"JAMA Oncol"},{"issue":"16","key":"zoi250910r26","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi250910r27","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa020989","article-title":"Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.","volume":"347","author":"Veronesi","year":"2002","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi250910r28","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2005.02.9975","article-title":"Prospective study of wide excision alone for ductal carcinoma in situ of the breast.","volume":"24","author":"Wong","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi250910r29","doi-asserted-by":"publisher","first-page":"TPS613","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS613","article-title":"NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS =18 breast cancer.","volume":"40","author":"White","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi250910r30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000505656","article-title":"Commercially available gene expression assays as predictive tools for adjuvant radiotherapy? A critical review.","volume":"15","author":"Krug","year":"2020","journal-title":"Breast Care (Basel)"},{"issue":"1","key":"zoi250910r31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1470-2045(24)00661-2","article-title":"Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.","volume":"26","author":"Meattini","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi250910r32","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/j.ejca.2013.02.031","article-title":"Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial.","volume":"49","author":"Blamey","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"zoi250910r33","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/cncr.33422","article-title":"Breast conservation among older patients with early-stage breast cancer: locoregional recurrence following adjuvant radiation or hormonal therapy.","volume":"127","author":"Tringale","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"zoi250910r34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/tbj.12150","article-title":"The relative benefits of tamoxifen in older women with T1 early-stage breast cancer treated with breast-conserving surgery and radiation therapy.","volume":"19","author":"Khan","year":"2013","journal-title":"Breast J"},{"issue":"4","key":"zoi250910r35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ijrobp.2019.07.052","article-title":"Lumpectomy plus hormone or radiation therapy alone for women aged 70 years or older with hormone receptor-positive early stage breast cancer in the modern era: an analysis of the National Cancer Database.","volume":"105","author":"Buszek","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839036\/miller_2025_oi_250910_1757519920.02077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:40Z","timestamp":1758121240000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.32305","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}